Trastuzumab conjugate - BioIntegratorAlternative Names: BI-CON-02
Latest Information Update: 01 Mar 2017
At a glance
- Originator BioIntegrator
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer
Most Recent Events
- 01 Sep 2016 Biointegrator initiates enrolment in a phase I trial for Breast cancer (Metastatic disease, Second-line therapy or greater) in Russia (NCT03062007)
- 05 Jul 2016 Phase-II clinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater) in Russia (IV)